Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from...
Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies
About this item
Full title
Author / Creator
Farokhnia, Mehdi , Rentsch, Christopher T. , Chuong, Vicky , McGinn, M. Adrienne , Elvig, Sophie K. , Douglass, Eliza A. , Gonzalez, Luis A. , Sanfilippo, Jenna E. , Marchette, Renata C. N. , Tunstall, Brendan J. , Fiellin, David A. , Koob, George F. , Justice, Amy C. , Leggio, Lorenzo and Vendruscolo, Leandro F.
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Evidence suggests that spironolactone, a nonselective mineralocorticoid receptor (MR) antagonist, modulates alcohol seeking and consumption. Therefore, spironolactone may represent a novel pharmacotherapy for alcohol use disorder (AUD). In this study, we tested the effects of spironolactone in a mouse model of alcohol drinking (drinking-in-the-dark...
Alternative Titles
Full title
Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10231646
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10231646
Other Identifiers
ISSN
1359-4184
E-ISSN
1476-5578
DOI
10.1038/s41380-022-01736-y
